Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck announces corporate restructuring
About 40% of the total reductions will occur in the US. To streamline management layers across the company, Merck will reduce its total number of senior and mid-level
About 40% of the total reductions will occur in the US. To streamline management layers across the company, Merck will reduce its total number of senior and mid-level
The company has reported net income of $1.14 billion for the third quarter of 2008, compared to $1.14 billion for the third quarter of 2007. Diluted earnings per
The new study, the first to be sponsored by the drug’s developers, will reconfirm dose ranging and will use the gold standard of the randomized, double-blind, placebo controlled
The expanded and updated results continue to indicate that picoplatin, given once every four weeks in combination with 5-fluorouracil and leucovorin (FOLPI), is associated with less frequent and
In preclinical studies, IPI-493 potently inhibits heat shock protein 90 (Hsp90) and has strong pharmaceutical properties in vitro and in vivo, including selectivity for cancer cells over normal
In advance of the marketing authorization application (MAA) submission, meetings with European Medicines Agency (EMEA) representatives, including the rapporteur countries, were convened to discuss the results from the
Preliminary results from 22 patients were reported in an ongoing Phase I clinical trial evaluating the safety and preliminary efficacy of TH-302 in patients with advanced solid tumors.
Discovered and developed by Astellas, Vaprisol, an arginine vasopressin receptor antagonist, is said to be the first and only approved drug indicated for the treatment of both euvolemic
The dispute between the competitors lasted for more than three years, with each party asserting that the other’s cold sore remedy advertising claims constituted false advertising in violation
The company anticipates the reporting of final results and statistical analysis for the study within the next two to three weeks. The new study concerns assessment of the